

Appendix Table F153 Comparative effectiveness of percutaneous tibial nerve stimulation versus extended-release tolterodine (results from overactive bladder innovative therapy trial)³⁵⁹

Outcome	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Subject assessment: cured	1/50	2/50	0.50 (0.05; 5.34)	-0.020 (-0.087; 0.047)		
Investigator assessment : cured	2/50	2/50	1.00 (0.15; 6.82)	0.000 (-0.077; 0.077)		
Subject assessment: improved	34/50	21/50	1.62 (1.11; 2.36)	0.260 (0.072; 0.448)	4 (2; 14)	260 (72; 448)
Subject assessment: cured or improved	35/50	23/50	1.52 (1.07; 2.16)	0.240 (0.052; 0.428)	4 (2; 19)	240 (52; 428)
Investigator assessment: improved	33/50	24/50	1.38 (0.97; 1.95)	0.180 (-0.011; 0.371)		
investigator assessment: cured or improved	35/50	26/50	1.35 (0.98; 1.86)	0.180 (-0.008 ;0.368)		
Withdrawn because treatment unsuccessful	0/50	3/50	0.14 (0.01; 2.70)	-0.060 (-0.134 ;0.014)		
Subject assessment no improvement/worsening	9/50	19/50	0.47 (0.24; 0.94)	-0.200 (-0.372; -0.028)	-5 (-35; -3)	-200 (-372; -28)
Investigator assessment no improvement/worsening	9/50	17/50	0.53 (0.26; 1.07)	-0.160 (-0.329; 0.009)		